Parent Project Muscular Dystrophy: Home: "GSK Now Recruiting for Exon 51 Clinical Trial in Non-Ambulatory Boys
This study will assess the pharmacokinetics, safety, and tolerability of GSK2402968 after a single administration, at escalating dose levels, in non-ambulatory boys with Duchenne who have a dystrophin gene mutation amenable to an exon 51 skip."
Thursday 17 March 2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment